Abstract
The high cost of management in schizophrenia, which includes direct and indirect costs, has triggered a good deal of interest in pharmacoeconomics of schizophrenia. The escalating cost of healthcare has led to capping of health services, including mental and psychiatric health. The recent introduction of second-generation antipsychotics has ignited an extensive debate about whether the benefits of such new and expensive medications justify the high acquisition costs. At the center of the pharmacoeconomics debates, health-related quality of life emerged as the optimum and most desirable outcome in the management of schizophrenia. One of the approaches proposed for cost-effectiveness studies capitalized on utility analysis concepts, which incorporates cost and quality of life. This chapter describes our feasibility study of applying utility concepts to schizophrenia, highlighting its merits and limitations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Awad AG, Voruganti LNP. Cost-utility analysis in schizophrenia. J Clin Psychiatry. 1999;60 Suppl 3:22–9.
Awad AG, Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877–93.
Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia – an update. Pharmacoeconomics. 2012;30:183–95.
Awad AG, Voruganti LNP. The impact of newer antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs. 2013;27:625–36.
Awad AG, Voruganti LNP, Heselgrave RJ. The aim of antipsychotic medications: what are they and are they being achieved? CNS Drugs. 1995;4:8–16.
Chouinard G, Albright P. Economic and health state utility determinations for schizophrenic patients treated with Risperidone or haloperidol. J Clin Psychopharmacol. 1997;17:298–307.
Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull. 1990;14:522–5.
Drummond MF, Davies L. Economic analysis alongside clinical trials, 1991. Int J Technol Assess Health Care. 1991;7:4561–73.
Drummond M, Stoddart G, Torrence G. Cost-utility analysis. In: Methods for the economic evaluation of health care programs. Oxford: Oxford Medical Publications; 1987. p. 113–38.
Froberg D, Kane R. Methodology for measuring health state preferences I measurement strategy. J Clin Epidemiol. 1989a;42:345–54.
Froberg D, Kane R. Methodology for measuring health state preferences II scaling methods. J Clin Epidemiol. 1989b;42:459–71.
Froberg D, Kane R. Methodology for measuring health state preferences III population and context effects. J Clin Epidemiol. 1989c;42:585–92.
Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systemic overview and motor-regression analysis. BMJ. 2000;321:1371–6.
Goeree R, O’Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J. The economic burden of schizophrenia in Canada. Can J Psychiatry. 1999;44:464–72.
Goeree R, Farahati F, Burke N, Blackhouse G, O-Reilly D, Pyne J, Tarride JE. The economic burden of schizophrenia in Canada 2004. Curr Med Res Opin. 2005;21:2017–28.
Hansen K, Toumi M, Francois C, Launois R. Pharmacoeconomic modelling in schizophrenia: trap or support for decision makers? Eur J Health Econ. 2006;7:19–29.
Hargreaves S. NICE guidelines address social aspects of schizophrenia. BMJ. 2003;29:326.
Jones PE, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst K, Murray R, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first generation drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS). Arch Gen Psychiatry. 2006;63:179–1087.
Knapp M. Costs of schizophrenia. Br J Psychiatry. 1997;171:509–18.
Leucht S, Wahelbeck K, Hamman J, Kissling W. New generation antipsychotics vs low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;36:1581–9.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz DB, Severe J, Hsiao JK. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med. 2005;22:1209–23.
Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10:231–48.
Ohlsen R, Taylor D, Tandon K, Aitehison KJ. Returning to the issue of the cost-effectiveness of antipsychotics in the treatment of schizophrenia. Clin Neuropsychiatry. 2008;5:184–94.
Revicki D, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, care givers and psychiatrists. Int Clin Psychopharmacol. 1996;11:101–8.
Revicki D, Brown RE, Keller M. Cost-effectiveness of new antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry. 1997;58:47–58.
Torrence GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1–30.
Von Neuman J, Morgenstern O. Theory of games and economic behaviour. Princeton: Princeton University Press; 1947.
Voruganti LNP, Awad AG, Oyewumi LK, Corfese L, Zirul S, Dhawan R. Assessing health utilities in schizophrenia – a feasibility study. Pharmaceconomics. 2000;17:273–86.
Wu EQ, Brinbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States 2002. J Clin Psychiatry. 2005;66:1122–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Awad, A.G., Voruganti, L.N.P. (2016). Quality of Life and Health Costs: The Feasibility of Cost-Utility Analysis in Schizophrenia. In: Awad, A., Voruganti, L. (eds) Beyond Assessment of Quality of Life in Schizophrenia. Adis, Cham. https://doi.org/10.1007/978-3-319-30061-0_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-30061-0_12
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-30059-7
Online ISBN: 978-3-319-30061-0
eBook Packages: MedicineMedicine (R0)